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An 81-year-old man was referred to our hospital because of a right renal tumor with vena cava thrombus
and multiple lung metastases that were detected by computed tomography (CT) scan during evaluation of
respiratory discomfort. We started medical treatment with sunitinib at a dose of 50 mg daily in a 2-week-
on, 1-week-off schedule after conﬁrming clear cell renal cell carcinoma by tumor biopsy. After 2-week
sunitinib treatment, thrombocytopenia continued and platelet count decreased to 1.8×109/l at day 11 after
stopping sunitinib. We needed to administer a total of 60 units platelet transfusion because of persistent
thrombocytopenia. Bone marrow aspiration did not reveal myelosuppression or carcinoma invasion to
bone marrow. Under the clinical diagnosis of drug-induced thrombocytopenia secondary to sunitinib, we
started immunoglobulin therapy at day 23 after stopping sunitinib. Platelet count returned to normal 10
days after starting immunoglobulin. The patient developed exacerbating lung metastasis and
carcinomatous lymphangiosis during subsequent course and died of renal cell carcinoma 79 days after
starting sunitinib. Thrombocytopenia after sunitinib therapy is often encountered but prolonged
thrombocytopenia is rare after stopping sunitinib. This case suggests that immunoglobulin therapy is
effective for drug-induced prolonged thrombocytopenia through immunological mechanism.
(Hinyokika Kiyo 62 : 73-76, 2016)








患 者 : 81歳，男性









入院時現症 : 身長 160 cm，体重 54 kg，腹部圧痛な
く，身体所見にも異常を認めなかった．Performance
status（PS）は 1 であった．
入院時検査所見 : LDH 202 U/l，クレアチニン 0.62
mg/dl と正常．ALP 309 U/l，CRP 3.70 mg/dl と上昇
を認めた．血算ではヘモグロビン 11.7 g/dl と軽度の
貧血を認めたが，白血球 9,640/μl，血小板 274×109/l
と正常範囲内だった．
入院後経過 : 以上より，臨床病期 T3bN0M1，











Fig. 1. CT showed a right renal tumor (A) with
vena cava thrombus (B) and multiple lung
metastases (C).
認後に，分子標的薬による全身治療を開始する方針と
した．腎腫瘍生検にて淡明細胞型 grade 3 であること
を確認後，肺塞栓予防のためIVCフィルターを留置
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Fig. 2. Clinical course during treatment.
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Fig. 3. Blood smear showed nearly normal number
of megakaryocytes and absence of carci-
noma invasion to bone marrow.
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